Early Contrast Enhancement: a novel Magnetic Resonance Imaging biomarker of pleural malignancy by Tsim, Selina et al.
Contents lists available at ScienceDirect
Lung Cancer
journal homepage: www.elsevier.com/locate/lungcan
Early Contrast Enhancement: A novel magnetic resonance imaging
biomarker of pleural malignancy
Selina Tsima,b, Catherine A. Humphreysc, Gordon W. Cowelld, David B. Stobod, Colin Noblee,
Rosemary Woodwardf, Caroline A. Kellyg, Laura Alexanderg, John E. Fosterf, Craig Dickc,
Kevin G. Blytha,h,⁎
a Pleural Disease Unit, Queen Elizabeth University Hospital, Glasgow, UK
b Institute of Cancer Sciences, University of Glasgow, UK
c Department of Pathology, Queen Elizabeth University Hospital, Glasgow, UK
d Department of Radiology, Queen Elizabeth University Hospital, Glasgow, UK
e Department of Radiology, Glasgow Royal Infirmary, Glasgow, UK
f Clinical Research Imaging Facility, Queen Elizabeth University Hospital, Glasgow, UK
g Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
h Institute of Infection, Immunity & Inflammmation, University of Glasgow, UK
A R T I C L E I N F O
Keywords:
Mesothelioma
Pleural malignancy
Pleural effusion
Magnetic resonance imaging
Biomarker
A B S T R A C T
Introduction: Pleural Malignancy (PM) is often occult on subjective radiological assessment. We sought to define
a novel, semi-objective Magnetic Resonance Imaging (MRI) biomarker of PM, targeted to increased tumour
microvessel density (MVD) and applicable to minimal pleural thickening.
Materials and methods: 60 consecutive patients with suspected PM underwent contrast-enhanced 3-T MRI then
pleural biopsy. In 58/60, parietal pleura signal intensity (SI) was measured in multiple regions of interest (ROI)
at multiple time-points, generating ROI SI/time curves and Mean SI gradient (MSIG: SI increment/time). The
diagnostic performance of Early Contrast Enhancement (ECE; which was defined as a SI peak in at least one ROI
at or before 4.5min) was compared with subjective MRI and Computed Tomography (CT) morphology results.
MSIG was correlated against tumour MVD (based on Factor VIII immunostain) in 31 patients with Mesothelioma.
Results: 71% (41/58) patients had PM. Pleural thickening was<10mm in 49/58 (84%). ECE sensitivity was
83% (95% CI 61–94%), specificity 83% (95% CI 68–91%), positive predictive value 68% (95% CI 47–84%),
negative predictive value 92% (78–97%). ECE performance was similar or superior to subjective CT and MRI.
MSIG correlated with MVD (r=0.4258, p= .02).
Discussion: ECE is a semi-objective, perfusion-based biomarker of PM, measurable in minimal pleural thickening.
Further studies are warranted.
1. Introduction
Radiological detection of pleural malignancy (PM) is frequently
difficult because overt pleural tumour may be occult and pleural effu-
sion may be the dominant, or only, feature [1]. This is particularly true
in early stage Malignant Pleural Mesothelioma (MPM), where extra-
pleural malignant features are frequently absent. Recent studies reflect
these challenges, reporting low sensitivity and considerable inter-ob-
server variation, using Computed Tomography (CT) in a routine clinical
setting [2,3].
Dynamic contrast-enhanced CT (DCE-CT) or perfusion CT allows
assessment of tumour microcirculation, including blood flow and ca-
pillary permeability [4]. Previous studies have demonstrated potential
utility in assessment of pulmonary nodules and MPM [5–7]. A major
advantage of perfusion CT is its widespread availability, however, the
multiplicity of protocols using different mathematical models [8] and
high radiation burden have limited its widespread use in routine clin-
ical practice to date [9,10].
Positron Emission Tomography (PET)-CT is a useful modality in
staging of thoracic malignancy, particularly when evaluating nodal and
distant metastatic disease, however its role in the differentiation of
benign and malignant pleural effusions is less well-established. Recent
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meta-analyses have demonstrated a pooled sensitivity of 81% and
specificity 74% for detecting PM, with considerable variation between
studies [11]. Tumours with low metabolic activity, such as early stage
epithelioid MPM are more likely to have a false negative PET-CT and
false positives in patients with inflammatory pleuritis, TB pleuritis and
previous pleurodesis are well recognised [12–14].
Efficient diagnosis is further complicated by the variable perfor-
mance of pleural cytology, which has a mean sensitivity of 60% (de-
pending on tumour type) but extremely low negative predictive value
(NPV) in MPM, for which histological confirmation remains mandatory
in most centres. Thoracoscopy offers excellent sensitivity, but is asso-
ciated with additional healthcare costs, increased procedure-related
risk and limited availability. Diagnostic delays are therefore common in
patients with PM.
A reliable, non-invasive imaging marker would be a major clinical
advance, allowing pathway rationalization and early direction of pa-
tients to thoracoscopy, including those with probable early-stage MPM.
Ideally, this should be objective, to improve reporting consistency, and
applicable to patients with minimal pleural thickening, since it would
offer limited additional value in cases with overt nodular disease.
Magnetic Resonance Imaging (MRI) is an attractive modality for this
purpose, facilitating both high contrast-resolution anatomical and
perfusion studies. Dynamic-Contrast-Enhanced MRI (DCE-MRI) exploits
the pathognomonic increase in blood vessel density typical of cancers
and related to neoangiogenesis [15–18]. DCE-MRI has previously been
used to reliably differentiate malignant from benign breast and prostate
lesions [18,19] and to generate prognostic [15–18] and predictive
(regarding response to anti-angiogenic chemotherapy) [20] data in
advanced MPM. However, DCE-MRI requires bulky pleural tumour for
application, making it unsuitable for early diagnostics. Neoangiogenesis
is an early biological event in tumourigenesis [21] and is therefore
likely to be present in patients with smaller pleural tumour volumes.
We hypothesised that novel MRI methodology targeted to increased
micro-vessel density (MVD) could accurately identify patients with PM,
including those with minimal pleural thickening.
2. Materials and methods
2.1. Study design
A prospective cohort study was performed, incorporating patients
recruited to an MRI pilot study and the DIAPHRAGM study (ISRCTN
registration 10079972), which contained an MRI sub-study. [22]
Table 1 summarises the objectives and a priori outcome measures.
Consecutive patients presenting to the Glasgow Pleural Disease Unit
were invited to participate (January 2013 − October 2016), based on
the following eligibility criteria.
• Inclusion criteria: 1) suspected PM requiring histological sampling
(by thoracoscopy or image-guided pleural biopsy); this was defined
by the presence of a unilateral pleural effusion, pleural thickening or
pleural mass lesion and non-diagnostic pleural fluid analysis (in-
cluding negative fluid cytology); 2) sufficient fitness for pleural
biopsy 3) informed written consent.
• Exclusion criteria: 1) pregnancy; 2) gadolinium allergy; 3) renal
impairment (eGFR<30ml/min); 4) known MRI contraindication
(e.g. cardiac pacemaker)
All patients underwent routine clinical work-up, [23] including
contrast-enhanced CT and pleural biopsy by local anaesthetic thor-
acoscopy (LAT), where technically possible. Video-assisted thoraco-
scopic surgery (VATS) or image-guided pleural biopsy were permitted
alternatives. Study procedures were limited to contrast-enhanced MRI
prior to pleural biopsy and measurement of tissue MVD using surplus
formalin-fixed, paraffin-embedded (FFPE) tissue, where available. The
study protocol was approved by the West of Scotland Research Ethics
Service (12/WS/0219, 13/WS/0240).
2.2. Sample size and assumptions
An a priori sample size calculation was not possible given the novel
nature of the primary contrast-enhanced MRI outcome measure. A
target sample size of 60 was deemed to be large enough for these
methods to be developed and tested. Assuming a 50% incidence of
MPM in the study cohort (based on our unit’s MPM incidence at LAT),
30 MPM patients would also allow a moderate correlation (r= 0.5)
between the relevant secondary outcome measures to be detected with
80% power at a 5% two-sided level of statistical significance.
2.3. MRI acquisition
66 patients underwent 3-Telsa MRI (Siemens Magnetom Verio or
Prisma® (Erlangen, Germany)). Imaging protocols were developed in
the first 6 patients, who did not receive contrast and are not included in
Table 1
Study objectives and outcome measures.
Study objective Outcome measures
Primary
To determine whether perfusion-based, ce-MRI can differentiate pleural malignancy from benign pleural disease
with comparable or superior sensitivity and specificity to subjective CT or MRI morphology assessment
Diagnostic classification based on
• MRI contrast enhancement pattern• CT morphology assessment• MRI morphology assessment
Diagnostic assessment including pleural biopsy results
Secondary
To determine whether there is a correlation between contrast enhancement pattern at MRI and tumour vascularity • Mean Signal Intensity Gradient at ce-MRI• Tumour MVD based on Factor VIII immunostaining in FFPE
pleural biopsies
• Inter-observer agreement (Cohen’s Kappa)• Intra-observer agreement for ECE only (Cohen’s Kappa)
To determine the reproducibility of ECE, CT and MRI morphology
Exploratory
To determine whether there is an association between:
1. ce-MRI parameters and Survival
2. Tumour vascularity and Survival
• MSIG at ce-MRI• Overall Survival (months)• Tumour MVD (Factor VIII immunostaining in FFPE pleural
biopsies)
• Overall Survival (months)
ce-MRI; Contrast-enhanced Magnetic Resonance Imaging, CT; Computed Tomography, ECE; Early Contrast Enhancement, FFPE; Formalin-Fixed Paraffin-Embedded; MVD; Micro-vessel
Density.
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any analyses. In the remaining 60 cases, isotropic, coronal T1-weighted,
fat saturated, 3D spoiled gradient echo sequences (repetition time
2.8–3.2 ms, echo time 1–1.1ms, field of view 400–440mm, matrix
224×100, flip angle 9°, slice thickness 1.8–1.9 mm, no inter-slice gap)
were acquired during a short breath-hold at end-inspiration. Images
were acquired at baseline and at 40 s, 80 s, 4.5min, 9min and 13.5 min
after injection of 0.1 mmol/kg gadobutrol contrast (Gadovist, Bayer,
Germany) at 2ml/s.
2.4. MRI analyses
2.4.1. Morphology
Each case was classified as benign or malignant by two experienced
thoracic radiologists (DS, GWC), based on morphology assessment
alone. The presence or absence of established morphological features of
PM, [24] including nodular or mediastinal pleural thickening, fissural
nodularity, pleural thickening> 1 cm and chest wall or diaphragmatic
invasion, was used to classify patients. Both radiologists were blinded to
the clinical and perfusion MRI data. A third thoracic radiologist (CN)
provided a casting classification in discordant cases.
2.4.2. Perfusion data
Perfusion analyses were performed by two senior respiratory phy-
sicians (ST and KGB), using OsiriX v5.8 (Pixmeo, Bernex, Switzerland).
KGB’s results were used solely to assess inter-observer agreement.
Repeat analyses by ST after a 2-month interval were used to assess
intra-observer agreement. Images were anonymised and both operators
were blinded to all other data. Up to 15 Regions of Interest (ROI) were
defined at each time point (Fig. 1(a) and (b)), using a track-ball mouse
and cursor, on representative areas of pleural disease. The pleura was
defined as the visible structure running parallel with, and medial to the
rib-cage and immediately contiguous with either aerated lung, pleural
fluid or air (depending on the presence of a fully expanded lung, pleural
effusion or pneumothorax, respectively at the imaged location). Care
was taken to constrain the boundaries of the ROI to the parietal pleura,
where possible, accepting that in cases where there was no pleural fluid
or air separating parietal and visceral pleura this could not be guar-
anteed. Once the required number of ROI (minimum of 5 in patients
with macro-nodular disease and 15 in patients with non-nodular dis-
ease) were defined on the 4.5-min post-contrast scan, these were elec-
tronically copied and pasted onto all other scans. Each scan was then
visually assessed and each operator was asked to make minor adjust-
ments to the position of each ROI to account for inconsistencies in the
patient’s breath-hold and chest wall position, where required.
In patients with macro-nodular disease, a minimum of 5, and up to
15 ROIs were placed on pleural mass lesions (Fig. 1(a)). The number
defined depended on the number of nodules; areas of necrosis were
avoided. In the absence of macro-nodular disease, 15 ROIs were placed
in all cases to ensure broad, random image sampling of the parietal
pleura given the absence of visual indicators of pleural tumour. These
ROI were defined consistently at anatomically similar locations in each
patient (Fig. 1(b–d)), and were distributed across 3 coronal slices:
1. Midpoint slice: the slice with the largest continuous length of par-
ietal pleura measured cranio-caudally. 9 ROIs were evenly dis-
tributed from cupula to costophrenic recess.
2. Anterior slice: the slice half-way from the midpoint slice to the most
anterior slice where parietal pleura was identifiable. 3 ROIs were
evenly distributed.
3. Posterior slice: the slice half-way from the midpoint slice to the most
posterior slice where parietal pleura was identifiable. 3 ROIs were
evenly distributed.
Signal intensity (SI) was measured within each ROI at each time
point, generating ROI SI/time plots (Fig. 1). SI measurements were
corrected for background signal noise using SI of extra-corporeal air.
Fig. 1. Contrast-enhanced, coronal, T1-weighted, fat-saturated, 3d spoiled gradient echo sequence Magnetic Resonance Images in two patients with Malignant Pleural Mesothelioma
(MPM) with highlighted Regions of Interest (ROI). (a) demonstrates a patient with overtly nodular pleural disease. (b) demonstrates a patient with effusion-dominant, low volume pleural
disease. Signal intensity/time curves for up to 15 ROI were plotted. (c) demonstrates an early peak in signal intensity at/before 4.5min (Early Contrast Enhancement (ECE)) in all ROI in a
patient with MPM. (d) demonstrates ECE in 9/15 ROI in a patient with MPM. (e) demonstrates no ECE in any ROI in a patient with Benign Asbestos Pleural Effusion (BAPE).
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The time point that SI peaked in each ROI and that Mean SI peaked in
each patient was recorded. This allowed computation of ROI SI gradient
(ROISIG) for each ROI, and Mean SI gradient (MSIG) for each patient:
= − ÷mean or ROI SI gradient peak SI baseline SI time to peak SI( ) ( )
MSIG was used to summarize ECE characteristics of each patient.
ROISIG was used in a post-hoc analysis to define the characteristics of
each ROI.
2.4.3. Early contrast enhancement
To define a contrast enhancement pattern typical of malignancy, SI/
time curves from the first 6 patients given gadobutrol with overtly
malignant, nodular pleural disease were reviewed. An early peak in SI
(occurring at or before 4.5min) was identified in all 6 mean SI/time
curves and 58/62 ROI SI/time curves from this cohort. This pattern was
termed ECE (see Fig. 1(c) for an example). ROI SI/time curves in the
remaining patients were then reviewed. ECE was deemed to be present,
and the patient classified as Malignant, if at least one ROI SI/time curve
demonstrated peak SI at/before 4.5min (Fig. 1(d)). This criterion was
chosen to replicate pleural biopsy interpretation where one malignant
biopsy classifies a patient as malignant, even if all other biopsies are
benign. If ECE was not identified in any ROI the patient was classified
as benign (Fig. 1(e)).
2.4.4. Post-hoc analyses regarding ROI signal intensity gradient (ROISIG)
Evidence of heterogeneous contrast enhancement (see Fig. 1(b))
prompted a post-hoc analysis to assess the contribution of benign (ECE-
negative) ROI to the discriminant performance of ECE. We interpreted
this as evidence of non-contiguous disease, commonly observed at
thoracoscopy. Receiver Operator Characteristic (ROC) curves were
plotted based on ROISIG for 1) all ROI in malignant cases relative to
patients with benign disease and 2) only ECE-positive ROI in patients
with malignancy relative to ROIs in benign cases.
2.4.5. Combined MRI morphology and ECE
To determine the value of combined MRI morphology and ECE
Fig. 2. Study flow chart summarising screening, recruitment and protocol completion.
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assessment, we classified patients using a 2-step approach: If morpho-
logical features of PM were present, the patient was classified as ma-
lignant, regardless of ECE findings. If MRI morphology was benign, then
ECE results were examined. If ECE was present, then the patient was
classified as malignant.
2.5. Contrast-enhanced CT
CT examinations were performed as part of routine clinical work-
up, 55/60 had venous-phase CT and 5/60 had CTPA examinations.
Scans were classified as malignant or benign based on the presence or
absence, respectively, of established features of PM, [1] including
nodular pleural thickening, pleural thickening> 1 cm, mediastinal
pleural thickening, enhancing pleural lesions, fissural nodularity,
pleural mass or infiltration of mediastinal structures, chest wall or
diaphragm, by the same experienced thoracic radiologists involved in
MRI morphology assessment (DS, GWC+/− CN) using VuePACS v11.4
(Carestream Health Inc., NY) in blinded fashion.
2.6. Measurement of tissue microvessel density
Surplus FFPE pleural tissue biopsies in MPM patients only were
examined by a Consultant Lung Pathologist (CD) to confirm that the
tissue was representative of the patient’s histological diagnosis. Sections
were cut on a digital microtome (4 μm thickness) and stained with
Factor VIII immunostain (Leica Biosystems, UK, 1:200 dilution). Slides
were digitized using Hamamatsu NDP (Hamamatsu, Welwyn Garden
City). MVD was measured using quantitative image analysis software
(Leica Biosystems, U.K.).
2.7. Statistical analyses
Data are described by mean (+/− SD) or median (inter-quartile
range), depending on distribution. Contingency tables were used to
calculate sensitivity, specificity, NPV and positive predictive value
(PPV) of all imaging end-points. Diagnostic performance between
methodologies was compared using McNemar’s test. Cohen’s Kappa
statistic was used to assess inter- and intra-observer agreement. ROC
curves were used to determine the diagnostic performance of ROISIG.
MVD was correlated against MSIG using Spearman’s rho test. A p
value≤ 0.05 was considered statistically significant and values were
adjusted for multiple comparisons using R v3.4. All other analyses were
performed using Graphpad Prism v7 and SPSS v22.0.
3. Results
3.1. Recruitment
Recruitment is summarised in Fig. 2. 58/60 patients completed the
planned contrast-enhanced-MRI protocol. 31/58 were diagnosed with
MPM, all of whom had surplus tissue available for MVD measurement.
3.2. Demographics and clinical findings
Median patient age was 76 (70–81) years, 51/58 (88%) were male
and 39/58 (67%) asbestos-exposed. 9/58 (16%) had a history of pre-
vious malignancy and 13/58 (22%) had pleural plaque disease.
36/58 (62%) had a final diagnosis of PM. 31/36 (86%) were diag-
nosed with MPM, of whom 65% (n= 20) had epithelioid MPM, 16%
(n= 5) sarcomatoid MPM, 13% (n=4) biphasic MPM and 6% (n=2)
had MPM not otherwise specified (NOS). 5/36 (14%) were diagnosed
with secondary pleural malignancy, of whom 60% (n=3) had meta-
static breast cancer and 40% (n=2) had metastatic lung cancer.
22/58 (38%) of patients had a final diagnosis of benign pleural
disease. Benign pleural diagnoses included BAPE (50%, n= 11), tu-
berculous pleurisy (14%, n= 3), fibrothorax (9%, n= 2), rheumatoid
pleurisy (9%, n=2), reactive effusion associated with lung cancer
(4.5%, n=1), post-lobectomy effusion (4.5%, n=1), secondary to
pulmonary thromboembolism (4.5%, n= 1) and drug-related (4.5%,
n=1).
Final diagnoses were based on histology from LAT in 46/58 (79%),
VATS in 7/58 (12%) and image-guided biopsy in 4/58 (7%). 1/58 (2%)
were diagnosed based on radiology, MDT consensus and interval
follow-up. All MPM cases were staged at regional MDT as I in 20/31
(64.5%), II in 0/31 (0%), III in 9/31 (29%) and IV in 2/31 (6.5%).
Median overall survival for patients with PM was 20 months. Mean
follow-up for patients with a benign pleural diagnosis was 20 (9)
months.
3.3. Primary objective
MRI and CT were performed a median of 1 (1–7) days and 20
(13–34) days prior to pleural biopsy, respectively. At MRI, 49/58 (84%)
patients had pleural thickening<10mm (median pleural thickness
5mm (4–7mm)) and 47/58 (81%) lacked gross tumour nodules. Mean
total scan duration was 35 (8) minutes. Contingency tables summar-
ising CT, MR imaging and clinical results are presented in online
Supplementary Table 1; associated diagnostic performance is sum-
marised in Table 2.
MRI perfusion analyses took a mean of 14 (3.5) minutes per patient;
involving a mean of 14 (3) ROI per patient. 12/12 (100%) PM cases
with macro-nodular disease were correctly classified as malignant
based on ECE. 21/24 (87.5%) PM cases with non-nodular, effusion-
dominant disease were correctly classified as malignant based on ECE.
All three false negative cases based on ECE had MPM (see online
Supplementary Table 2). Two cases were initially thought to be benign
at LAT but developed progressive pleural thickening, prompting repeat
biopsies and diagnoses of Epithelioid MPM (after 9 and 6 months re-
spectively), with final classification as malignant. In both cases, this PM
diagnosis was consistent with their initial positive ECE result. Both
Table 2
The diagnostic performance and reproducibility of CT morphology, MRI morphology and MRI-Early Contrast Enhancement (ECE) assessed in 58 patients with suspected Pleural
Malignancy. Agreement was assessed using Cohen’s Kappa statistic. Diagnostic performance between groups is compared by McNemar’s test, adjusted for multiple comparisons.
Statistically significant differences before and after adjustment are highlighted below.
CT Morphology MRI Morphology MRI-ECE Combined MRI Morphology-ECE
Sensitivity (95% CI) 56% (37–72%) 68% (48–83%) 83%* (61–94%) 92%** (67–100%)
Specificity (95% CI) 77% (60–89%) 85% (69–93%) 83% (68–91%) 78% (64–87%)
PPV (95% CI) 68% (47–84%) 77% (57–90%) 68% (47–84%) 55% (35–73%)
NPV (95% CI) 67% (50–80%) 78% (62–88%) 92% (78–97%) 97% (86–100%)
Inter-observer Agreement 0.65 0.593 0.784 N/R
Intra-observer Agreement N/R N/R 0.864 N/R
CT; Computed Tomography, MRI; Magnetic Resonance Imaging, CI; Confidence Interval, PPV; Positive Predictive Value, NPV; Negative Predictive Value, N/R; Not Recorded.
* Unadjusted p value .022 but adjusted p value .066 (MRI-ECE vs. CT morphology).
** Unadjusted p value .016 but adjusted p value .66 (Combined MRI morphology and ECE assessment vs. MRI morphology). For all other comparisons p > .05.
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were classified as benign based on MRI morphology and one was
classified as benign on CT morphology.
3.4. Secondary objectives
Results for inter- (and intra-) observer agreement regarding MR and
CT end-points are summarised in Table 2. MSIG was significantly higher
in patients with PM (0.58 (0.27–0.88) AU/s) than benign disease (0.2
(0.06–0.29) AU/s, p < .0001). In patients with MPM, there was a
positive correlation between MSIG and MVD (r= 0.4258, p= .02,
Fig. 4(b)). This relationship was preserved, and appeared more pow-
erful when this correlation was confined to MPM patients without
macro-nodular disease (r= 0.6594, p= .003, n=18).
3.5. Exploratory objectives
3.5.1. Micro-vessel density in FFPE tissue
Median tissue MVD in patients with MPM was 0.008761. Patients
with a higher MVD (>0.008761) had significantly poorer median
survival in comparison to those with lower MVD (10 months vs. 20
months, HR 2.723 (95% CI 1.093–6.784), p= .03), see (Fig. 4(c)).
3.5.2. Mean signal intensity gradient at MRI
Median MSIG in patients with MPM was 0.533AU/s. Patients with a
high MSIG (> 0.533AU/s) had poorer median survival than those with
a low MSIG (12 months vs. 20 months, HR 1.898 (95% CI
0.8349–4.316), p= 0.047 (Fig. 4(d)).
3.6. Post-hoc analyses regarding ROI signal intensity gradient
A ROC curve plotted using only ROISIG data from ECE-positive ROI
(n=273) demonstrated optimum sensitivity (90% (95% CI 86–94%))
and specificity (86% (95% CI 81–89%)) at a threshold of
ROISIG>0.43 AU/sec (AUC 0.938, (95% CI 0.918–0.957), p < .0001,
see Fig. 3(a)). Using all ROISIG data (n= 482), regardless of ECE result,
a ROISIG > 0.29 AU/sec provided optimum, but reduced sensitivity
(71% (95% CI 67–75%)), specificity (68% (95% CI 63–73%)) and dis-
criminatory performance (AUC 0.776 (95% CI 0.744–0.808),
p < .0001, Fig. 3(b)).
4. Discussion
In this study, we have described the acquisition and preliminary
diagnostic performance of a novel, semi-objective MRI biomarker of
PM. ECE demonstrated higher diagnostic sensitivity (83%) and NPV
(92%) than subjective CT morphology without perfusion analysis (56%
and 67%, respectively) and MRI morphology (68% and 78%, respec-
tively). After adjustment for multiple comparisons, these differences did
not reach statistical significance. Combining MRI morphology with ECE
resulted in slightly reduced specificity (78%) and PPV (55%) than with
ECE alone (83% and 68%, respectively). ECE was associated with su-
perior inter-observer agreement (κ 0.784) relative to CT (κ 0.65) and
MRI morphology (κ 0.593).
ECE was defined as a peak in signal intensity at/before 4.5 min
(270 s) post-gadolinium contrast. This time-point is later than the cur-
rently recommended timing for pleural CT acquisition following iodi-
nated contrast administration (60 s). [25–28] Tissue enhancement after
gadolinium, which is an extracellular contrast agent, is dependent on
several factors, including vascular perfusion, interstitial contrast uptake
and clearance, and vascular permeability. [29,30] In this study, MSIG
correlated positively with tissue MVD, suggesting this was a major
contributor to the enhancement pattern observed. However, this ana-
lysis was confined to MPM cases and other factors, including delayed
contrast clearance from peri-tumoural stroma may have contributed to
the ‘delayed’ peak contrast enhancement observed. MPM is char-
acterised by extensive peri-tumoural stroma, containing moderately
cellular fibrous tissue. [31] Therefore these mechanisms should be
further explored in future larger studies. Since ECE was defined based
on observations in patients with macro-nodular tumour (MPM in 5/6,
secondary PM in 1/6) it is possible that a different definition may
perform better in patients with lower volume pleural tumour or in
cancers of different types, in which different microvascular or other
features predominate. However, the correlation we observed between
tissue MVD and MSIG in MPM (r=0.4258, p=0.02, n=28) appeared
preserved, and indeed more powerful, when this analysis was confined
to patients without macro-nodules (r= 0.6594, p=0.003, n=18).
Furthermore, the 4.5min SI peak observed here is concordant with a
recent retrospective MRI study involving MPM patients, in which peak
tumour enhancement occurred at 280 s post-gadolinium administration
[32].
The diagnostic performance of ECE was similar to two earlier MRI
morphology studies, in which pleural hyper-intensity on T1-weighted
gadolinium-enhanced images accurately discriminated malignant from
benign pleural disease. [33,34] These studies also reported similar false
positive results in patients with tuberculous pleurisy, possibly reflecting
angiogenesis in active tuberculous lesions. [35,36] However, it is im-
portant to note that the patients in these earlier studies had pleural
thickening> 10mm, or pleural thickening that was significant, but not
Fig. 3. Receiver Operating Characteristic (ROC) curves of Region of Interest Signal Intensity Gradient (ROISIG) measured in 58 patients with suspected pleural malignancy (PM) using
MRI. In (a), all ROI are included, including those who failed to demonstrate an Early Contrast Enhancement (ECE) pattern. In (b), only ROI demonstrating ECE in patients with PM are
included, resulting in an improved discriminative performance.
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specifically measured. These older techniques therefore offered little
additional diagnostic value over standard morphology, and have not
entered clinical practice. DCE-MRI, mentioned earlier [16,18] is also
poorly suited to early diagnosis, since it requires bulky disease for ap-
plication. [20] Our data suggest that ECE is, potentially, a more useful
diagnostic tool since the median pleural thickness in this study was
5mm. Despite this, ECE was measurable in all patients and produced
similar diagnostic performance to these earlier studies of more ad-
vanced pleural disease [33,34].
Similar to the findings in the present study, quantitative perfusion
parameters at DCE-CT have been shown to correlate with tumour MVD.
[37–39] Previous studies have reported on the potential utility of per-
fusion CT in the differentiation of benign from malignant pulmonary
nodules. [40] In addition, results from a pilot study assessing DCE-CT in
13 patients with MPM, imaging a 5.5 cm axial extent of the thorax,
reported correlation of contrast uptake with tumour burden and dif-
ferential contrast uptake in patients undergoing chemotherapy versus
observation alone. [7] However, the role of perfusion CT in the dif-
ferentiation of PM from benign pleural disease has not been widely
studied.
A potential advantage of perfusion CT over MRI- ECE, described
here, is the greater availability of CT scanners and a quicker acquisition
time. However, current perfusion CT methods do not allow complete
assessment of the entire pleura, as is reported here using MRI, since
perfusion CT is currently limited to defined sections of the thorax.
Furthermore, high radiation exposure has so far limited clinical de-
ployment of perfusion CT on a routine basis. [9,10]
PET-CT also offers potential advantages over the MRI methods re-
ported here. In MPM, PET-CT out-performs both CT and MRI in as-
sessment of nodal and distant metastases. [41] In addition, previous
studies report elevated maximal standardised uptake values (SUVmax),
in PM, relative to benign disease and high sensitivity and specificity
(pooled sensitivity of 95% and specificity of 82%) in a meta-analysis
[42], However, PET-CT specificity is reduced in TB pleuritis [43], as is
reported here for MRI-ECE, and following talc pleurodesis [44–46].
PET-CT sensitivity is also reduced in early stage MPM, and epithelioid
sub-types. [11,42] This significantly limits the utility of PET-CT as an
early diagnostic test, particularly in effusion-dominant cases of MPM,
which are most commonly of epithelioid origin.
The diagnostic performance of CT morphology reported here (sen-
sitivity 56%, specificity 77%) is concordant with two recent studies
(sensitivity 68%, specificity 78% [2] and sensitivity 68%, specificity
80%) [3] that retrospectively reported CT performance in routine
practice, based on extracted reports. The current study involved pro-
spective research-specific reporting by expert thoracic radiologists, but
reported similar results. These are considerably inferior to those of
older studies (e.g. sensitivity 92%, specificity 87%). [47] The same was
true for our MRI morphology results (sensitivity 68%, specificity 85%)
relative to previous studies, which reported sensitivity up to 96% and
specificity up to 80%. [47–50] These differences probably reflect earlier
stage/lower volume PM in the current study, but highlight that mor-
phology reporting is operator-dependent and subjective. Our finding of
improved inter-observer agreement using ECE, a semi-objective mea-
surement, is therefore an important outcome.
Similar to previous reports, increasing tumour MVD was associated
with poorer survival in MPM. [51,52] Concordantly, increasing MSIG
was also associated with worse outcomes. Our measurements were
performed prior to any intervention that could have altered the pleural
microcirculation, including pleurodesis or chemotherapy. This supports
a conclusion that ECE is perfusion-based, although further studies fo-
cused on contrast enhancement mechanisms are required.
4.1. Potential clinical implications
While MRI is becoming increasingly available, the ability to assess
patients with suspected MPM with thoracoscopy remains relatively
limited to specialist centres. If validated in larger studies, ECE may
improve the accuracy of pleural imaging in cases of suspected MPM.
This may allow pathway rationalization, directing patients appro-
priately to specialist centres and early invasive sampling, including
early thoracoscopy when MPM appears likely. The results of our ROISIG
post-hoc analyses suggest that benign (ECE-negative) ROI in patients
with PM negatively contribute to discriminant performance. This is
consistent with a hypothesis that these data originate from areas of
interspersed benign disease in patients with discontinuous malignant
pleural lesions, which are commonly observed at thoracoscopy.
Measurement of SI and assessment of ECE behavior across the entire
pleura using a volumetric approach could be developed in future
Fig. 4. Paraffin-embedded pleural biopsies were stained with Factor VIII immunostain (a), Panel A). Computer software was used to detect the immunostain and calculate Microvessel
Density (MVD) (a), Panel B). Mean Signal Intensity Gradient (MSIG) was measured by contrast enhanced-Magnetic Resonance Imaging in 31 patients with a final diagnosis of Malignant
Pleural Mesothelioma (MPM) and correlated against MVD (b). Higher tumour MVD and MSIG in patients with MPM were associated with adverse survival (c) and (d), respectively).
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studies. Theoretically, this would allow the pleura to be treated as a
‘single ROI’. Pleural SIG, being a continuous variable like ROISIG, could
then be applied at different thresholds depending on the clinical con-
text. For example, a lower threshold (maximizing sensitivity) could be
used in a pleural staging population vs. a higher threshold (maximizing
specificity) for screening of asbestos-exposed persons for early MPM.
4.2. Study limitations
The principal limitation is the relatively small sample size, reflected
in relatively wide confidence intervals around some measures of diag-
nostic performance. Nevertheless, we have assessed ECE in large
number of individual ROI (n= 814) using a technique which appears
reproducible. A second limitation is that although ECE is objectively
defined, the user-defined ROI from which SI is measured are not. Our
pre-defined strategy for ROI definition was devised to minimize varia-
tion and mirror thoracoscopic tissue sampling, but is a source of po-
tential inconsistency. A volumetric approach could theoretically over-
come this, but would require further development. An additional
limitation is that we did not perform perfusion CT assessment for
comparison with ECE, as all CT imaging in this study was performed as
part of routine clinical work-up. However, as previously discussed,
perfusion CT has not yet been widely studied in PM and is not routinely
used in the assessment of patients with suspected PM in most centres at
present. Finally, ECE analysis, although not laborious, is slower than
morphology assessment. Technique evolution, including increased au-
tomation should reduce analysis time.
5. Conclusion
In this preliminary study, ECE appeared to be a sensitive, specific
and reproducible biomarker of PM, with a high NPV, meriting further
assessment in a large multi-centre study. ECE appears predominantly
related to increased MVD in patients with MPM, although more precise
information regarding contrast enhancement mechanisms is required.
ECE methodology is applicable to patients with minimal pleural
thickening, making this biomarker a potentially useful tool in effusion-
dominant, low-volume PM, including early-stage MPM.
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